Lumiliximab, also known as ST-152, represents a novel antibody targeting the soluble receptor for IL -13. This compound demonstrates significant potential in managing fibrotic conditions , particularly https://deniswwal012633.activoblog.com/51469833/lumiliximab-a-thorough-dive-into-the-st-152-biologic